Determining best potential predictor during high-dose progestin therapy for early staged and well-differentiated endometrial adenocarcinoma using semiquantitative analysis based on image processing and immunohistochemistry

Journal of Nippon Medical School

Volumn 78, Issue 2, 2011, Pages 84-95

  Kamoi, Seiryu ^a   Ohaki, Yoshiharu ^b   Mori, Osamu ^b   Yamada, Takashi ^a   Fukunaga, Masaharu ^c   Takeshita, Toshiyuki ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

High dose progestin therapy; Immunohistochemistry; Medroxyprogesterone acetate; Semiquantitative analysis; Uterine preservation

Indexed keywords

EOSIN; ESTROGEN RECEPTOR; HEMATOXYLIN; KI 67 ANTIGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE RECEPTOR; SINGLE STRANDED DNA;

ADULT; APOPTOSIS; ARTERY EMBOLISM; ARTICLE; CANCER HORMONE THERAPY; CELL SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; ENDOMETRIUM CARCINOMA; EPITHELIUM CELL; FATIGUE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTERECTOMY; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; LUNG EMBOLISM; NAUSEA; PREDICTOR VARIABLE; QUANTITATIVE ANALYSIS; STROMA CELL; TREATMENT RESPONSE; TUMOR BIOPSY;

ADENOCARCINOMA; ADULT; CA-125 ANTIGEN; CELL DIFFERENTIATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; NEOPLASM STAGING; PROGESTINS;

EID: 79955439804     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.78.84     Document Type: Article

References (14)

1. Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ: Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 1997; 79: 320-327.
2. Randall TC, Kurman RJ: Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997; 90: 434-440.
3. Fujiwara H, Shibahara H, Usui R, et al.: Unsuspected uterine carcinosarcoma (heterologous) diagnosed following conservative therapies with medroxyprogesterone acetate for presumed earlystage endometrial carcinoma. Am J Reprod Immunol 2002; 47: 129-131.
4. Kamoi S, Ohaki Y, Mori O, Kurose K, Fukunaga M, Takeshita T: Serial histological observation of endometrial adenocarcinoma treated with high-dose progestin until complete disappearance of carcinomatous foci-Review of more than 25 biopsies from 5 patients. Int J Gynecol Cancer 2008; 18: 1305-1314.
5. Silverberg SG, Kurman RJ: Endometrial Carcinoma. In: Rosai, ed. Tumors of the Uterine Corpus and Gestational Trophoblastic Disease: atlas of tumor pathology fascicle 3, 1992; pp 47-89, Armed Forces Institute of Pathology, Washington DC.
6. Kumar V, Abbas AK, Fausto N: Cellular adaptations, cell injury and cell death. In Robbins & Cotran Pathologic Basis of Disease (Kumar V, Abbas AK, Fausto N, eds), 7th ed. 2004; pp 3-46, Elsevier Saunders, New York.
7. Amin MR, Kurosaki M, Watanabe T, Tanaka S, Hori T: A comparative study of MIB-1 staining indices of gliomas measured by NIH Image analysis program and conventional manual cell counting method. Neurol Res 2000; 22: 495-500.
8. Ide M, Jimbo M, Yamamoto M, Kubo O: Tumor cell counting using an image analysis program for MIB-1 immunohistochemistry. Neurol Med Chir (Tokyo) 1997; 37: 158-162.
9. Yamaji K, Fujimoto S, Ikeda Y, et al.: Apoptotic myocardial cell death in the setting of arrhythmogenic right ventricular cardiomyopathy. Acta Cardiol 2005; 60: 465-470.
10. Groos S, Reale E, Luciano L: General suitability of techniques for in situ detection of apoptosis in small intestinal epithelium. Anat Rec A Discov Mol Cell Evol Biol 2003; 272: 503-513.
11. Ehrlich CE, Young PC, Cleary RE: Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications. Am J Obstet Gynecol 1981; 141: 539-546.
12. Yamazawa K, Hirai M, Fujito A, et al.: Fertilitypreserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 2007; 22: 1953-1958.
13. Yang YC, Wu CC, Chen CP, Chang CL, Wang KL: Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer. Gynecol Oncol 2005; 99: 287-293.
14. Zaino RJ, Clarke CL, Mortel R, Satyaswaroop PG: Heterogeneity of progesterone receptor distribution in human endometrial adenocarcinoma. Cancer Res 1988; 48: 1889-1895.